Found: 69
Select item for more details and to access through your institution.
Author Correction: Integrated genomics point to immune vulnerabilities in pleural mesothelioma.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Integrated genomics point to immune vulnerabilities in pleural mesothelioma.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-98414-w
- By:
- Publication type:
- Article
Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer.
- Published in:
- Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-30908-1
- By:
- Publication type:
- Article
Genomic analysis defines distinct pancreatic and neuronal subtypes of lung carcinoid.
- Published in:
- Journal of Pathology, 2024, v. 264, n. 3, p. 332, doi. 10.1002/path.6352
- By:
- Publication type:
- Article
Assessing the sensitivity and acceptability of the Royal Marsden Palliative Care Referral “Triggers” Tool for outpatients with cancer.
- Published in:
- Supportive Care in Cancer, 2024, v. 32, n. 11, p. 1, doi. 10.1007/s00520-024-08921-5
- By:
- Publication type:
- Article
Treatment decision for recurrences in non-small cell lung cancer during or after adjuvant osimertinib: an international Delphi consensus report.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2023.1330468
- By:
- Publication type:
- Article
Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer.
- Published in:
- Pharmacogenomics & Personalized Medicine, 2014, v. 7, p. 285, doi. 10.2147/PGPM.S55339
- By:
- Publication type:
- Article
A pilot study of a novel home telemonitoring system for oncology patients receiving chemotherapy.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Durable response of multiple myeloma and non‐small cell lung cancer with simultaneous, biologically targeted treatment.
- Published in:
- British Journal of Haematology, 2020, v. 189, n. 1, p. e1, doi. 10.1111/bjh.16393
- By:
- Publication type:
- Article
Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy.
- Published in:
- 2018
- By:
- Publication type:
- journal article
An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Supersensitive Mutation: Two Case Reports of Non-Small-Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
- Published in:
- Clinical Lung Cancer, 2010, v. 11, n. 5, p. E5, doi. 10.3816/CLC.2010.n.047
- By:
- Publication type:
- Article
Hyperglycaemia following immune checkpoint inhibitor therapy—Incidence, aetiology and assessment.
- Published in:
- Diabetic Medicine, 2023, v. 40, n. 4, p. 1, doi. 10.1111/dme.15053
- By:
- Publication type:
- Article
Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.
- Published in:
- Lung Cancer: Targets & Therapy, 2024, v. 15, p. 87, doi. 10.2147/LCTT.S463429
- By:
- Publication type:
- Article
Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma.
- Published in:
- Drugs, 2021, v. 81, n. 9, p. 971, doi. 10.1007/s40265-021-01506-0
- By:
- Publication type:
- Article
Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer.
- Published in:
- Drugs, 2017, v. 77, n. 8, p. 813, doi. 10.1007/s40265-017-0732-2
- By:
- Publication type:
- Article
Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach.
- Published in:
- PLoS ONE, 2015, v. 10, n. 9, p. 1, doi. 10.1371/journal.pone.0139074
- By:
- Publication type:
- Article
Excision Repair Cross-Complementation Group 1 (ERCC1) Status and Lung Cancer Outcomes: A Meta-Analysis of Published Studies and Recommendations.
- Published in:
- PLoS ONE, 2011, v. 6, n. 10, p. 1, doi. 10.1371/journal.pone.0025164
- By:
- Publication type:
- Article
Transportability of Overall Survival Estimates From US to Canadian Patients With Advanced Non–Small Cell Lung Cancer With Implications for Regulatory and Health Technology Assessment.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 11, p. e2239874, doi. 10.1001/jamanetworkopen.2022.39874
- By:
- Publication type:
- Article
Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non–Small Cell Lung Cancer.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 5, p. e2214046, doi. 10.1001/jamanetworkopen.2022.14046
- By:
- Publication type:
- Article
Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non–Small Cell Lung Cancer.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 5, p. 1, doi. 10.1001/jamanetworkopen.2022.14046
- By:
- Publication type:
- Article
Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 1, p. 112, doi. 10.3390/jcm12010112
- By:
- Publication type:
- Article
Re: Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK).
- Published in:
- JNCI: Journal of the National Cancer Institute, 2005, v. 97, n. 24, p. 1855, doi. 10.1093/jnci/dji445
- By:
- Publication type:
- Article
Re: Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis.
- Published in:
- 2005
- By:
- Publication type:
- Letter
Atezolizumab‐induced linear IgA bullous dermatosis.
- Published in:
- British Journal of Dermatology, 2022, v. 187, n. 6, p. e193, doi. 10.1111/bjd.21653
- By:
- Publication type:
- Article
Lung Cancer Related Thrombosis (LCART): Focus on Immune Checkpoint Blockade.
- Published in:
- Cancers, 2024, v. 16, n. 2, p. 450, doi. 10.3390/cancers16020450
- By:
- Publication type:
- Article
Amivantamab Compared with Real-World Physician's Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating EGFR Exon 20 Insertion Mutations.
- Published in:
- Cancers, 2023, v. 15, n. 22, p. 5326, doi. 10.3390/cancers15225326
- By:
- Publication type:
- Article
A Subset of Non-Small Cell Lung Cancer Patients Treated with Pemetrexed Show 18 F-Fluorothymidine "Flare" on Positron Emission Tomography.
- Published in:
- Cancers, 2023, v. 15, n. 14, p. 3718, doi. 10.3390/cancers15143718
- By:
- Publication type:
- Article
Risk of non-medullary thyroid cancer influenced by polymorphic variation in the thyroglobulin gene.
- Published in:
- Carcinogenesis, 2004, v. 25, n. 3, p. 369
- By:
- Publication type:
- Article
Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications.
- Published in:
- Therapeutic Advances in Medical Oncology, 2017, v. 9, n. 3, p. 201, doi. 10.1177/1758834016687262
- By:
- Publication type:
- Article
Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice.
- Published in:
- BMC Research Notes, 2015, v. 8, p. 1, doi. 10.1186/s13104-015-1675-x
- By:
- Publication type:
- Article
A prospective observational study of on-treatment plasma homocysteine levels as a biomarker of toxicity, depression and vitamin supplementation lead-in time pre pemetrexed, in patients with non-small cell lung cancer and malignant mesothelioma.
- Published in:
- PLoS ONE, 2019, v. 14, n. 11, p. 1, doi. 10.1371/journal.pone.0225509
- By:
- Publication type:
- Article
The efficacy of crizotinib in patients with ALK-positive nonsmall cell lung cancer.
- Published in:
- Therapeutic Advances in Respiratory Disease, 2015, v. 9, n. 3, p. 97, doi. 10.1177/1753465815577738
- By:
- Publication type:
- Article
Updates in Management of Malignant Pleural Mesothelioma.
- Published in:
- Current Treatment Options in Oncology, 2023, v. 24, n. 12, p. 1758, doi. 10.1007/s11864-023-01148-2
- By:
- Publication type:
- Article
Correction to: Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease.
- Published in:
- 2021
- By:
- Publication type:
- corrected article
Mucinous adenocarcinoma arising in congenital pulmonary airway malformation: clinicopathological analysis of 37 cases.
- Published in:
- Histopathology, 2021, v. 78, n. 3, p. 434, doi. 10.1111/his.14239
- By:
- Publication type:
- Article
Presence of pleomorphic features but not growth patterns improves prognostic stratification of epithelioid malignant pleural mesothelioma by 2‐tier nuclear grade.
- Published in:
- Histopathology, 2020, v. 77, n. 3, p. 423, doi. 10.1111/his.14127
- By:
- Publication type:
- Article
A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Y disruption, autosomal hypomethylation and poor male lung cancer survival.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-91907-8
- By:
- Publication type:
- Article
Distributional Cost-Effectiveness Analysis of Treatments for Non-Small Cell Lung Cancer: An Illustration of an Aggregate Analysis and its Key Drivers.
- Published in:
- PharmacoEconomics, 2023, v. 41, n. 8, p. 1011, doi. 10.1007/s40273-023-01281-8
- By:
- Publication type:
- Article
Correction to: The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care.
- Published in:
- British Journal of Cancer, 2023, v. 128, n. 2, p. 161, doi. 10.1038/s41416-022-02107-8
- By:
- Publication type:
- Article
Palliative treatments for patients with inoperable gastroesophageal cancers.
- Published in:
- International Journal of Palliative Nursing, 2006, v. 12, n. 7, p. 306, doi. 10.12968/ijpn.2006.12.7.21606
- By:
- Publication type:
- Article
Time Trends in the Outcome of Elderly Patients with Breast Cancer.
- Published in:
- Breast Journal, 2008, v. 14, n. 2, p. 158, doi. 10.1111/j.1524-4741.2007.00547.x
- By:
- Publication type:
- Article
Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapy.
- Published in:
- PLoS ONE, 2022, v. 17, n. 7, p. 1, doi. 10.1371/journal.pone.0270950
- By:
- Publication type:
- Article
Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Hyperprogression with immunotherapy: Is it real?
- Published in:
- Cancer (0008543X), 2019, v. 125, n. 8, p. 1218, doi. 10.1002/cncr.31997
- By:
- Publication type:
- Article